Vesey Street said to make more than 10x on Imedex sale, first full exit


Vesey Street Capital Partners, Imedex, cancer, healthcare, private equity, merger, M&A, Susquehanna Growth Equity, HMP
  • Healthcare PE firm bought Imedex in 2015
  • Vesey targets companies generating $10 mln-$25 mln EBITDA
  • Acquirer HMP preempted a formal sales process
Vesey Street Capital Partners stands to make more than 10x its investment through the sale of Imedex, its first full exit, Buyouts has learned. Healthcare-services-focused Vesey sold Imedex just two years after buying the provider of medical education for oncologists. The ...

This content is available for Buyouts subscribers only. Request a free trial to get access for a limited period

If you already have an active Buyouts subscription, please sign in to view this article.

Digital Edition

BO_092517_cover

To read a digital copy of our latest magazine

click here

PE News Briefs